A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Recruiting · NCT05744466 · Observational (researchers observe without assigning treatment) · Lead sponsor: Bristol-Myers Squibb
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Have been diagnosed with plaque psoriasis by a dermatologist
- Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
- Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes
Exclusion criteria
- Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
- Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
Where it is running
1 location listed across 1 US state.
- Local Institution - Waltham, Massachusetts, United States